mutation in different haematopoietic lineages are markedly distinct. BRAF(V600E) expression in HSCs can cause a tumoural disease, but results in a neurodegenerative inflammatory disorder when ...

Lee Moffitt Cancer Center and Research Institute in Florida, explains the latest approach to treating patients with melanoma with BRAF mutations, including those whose disease has spread to the ...

An ongoing clinical trial called "BREAKWATER" is showing great promise for metastatic colon cancer patients with a particular ...

PLX4032 induced complete or partial tumor regression in 81% of patients who had melanoma with the V600E BRAF mutation. Responses were observed at all sites of disease, including the bone ...

The latest readout from the BREAKWATER study showed "unprecedented" median overall survival of 30.3 months for Braftovi-Erbitux-chemo.

It is a niche indication, given that BRAF mutations are estimated to occur in just 8% to 10% of people with metastatic colorectal cancer, but an important development for patients as these tumours ...

SAN FRANCISCO -- First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF ...

Now, these patients tend to have very metastatic disease, and we obviously want to help them ... is the addition of chemotherapy in treatment-naive patients with a BRAF V600E mutation in their ...

In disease models, data demonstrated broad anti-tumor efficacy of NRX-0305 across all three BRAF mutation classes and in tumors that are resistant to existing therapies. Specifically, NX-0305 ...